07:00 , Jun 17, 2013 |  BioCentury  |  Finance

Living the dream

PeptiDream Inc. (Tokyo:4587) jumped over 400% in its first week of trading, but due to rules on daily price limits, there's no telling what investors are really willing to pay for the company. The preclinical...
08:00 , Feb 11, 2013 |  BioCentury  |  Finance

Bubbling up in Japan

Japan's biotech stocks have benefited from a spike in interest from retail investors driven in part by last October's Nobel Prize for a Kyoto University stem cell researcher. Company executives who spoke with BioCentury are...
08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Darwin's delight

The biotech ecosystem looks healthy moving into 2013. With the space above $1 billion more than replenished in 2012, mid-cap names have money to create their own tier-jumping stories this year, while investors see natural...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Financial News

Gene Techno Science completes IPO

Gene Techno Science Co. Ltd. (Tokyo:4584), Sapporo, Japan   Business: Cancer, Autoimmune, Musculoskeletal   Date completed: 11/30/12   Type: IPO   Raised: ¥696 million ($8.4 million)   Shares: 580,000   Price: ¥1,200   Shares after...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Clinical News

iBio preclinical data

iBio said it used its iBioLaunch technology to produce a functional biosimilar of palivizumab, a humanized mAb against RSV F protein . In vitro, the plant-produced biosimilar displayed dose-dependent neutralizing activity against RSV in a...
07:00 , Jul 9, 2007 |  BC Week In Review  |  Company News

Gene Techno Science, Kaken deal

Gene Techno granted Kaken an exclusive, worldwide license to develop, manufacture and market antibodies that target integrin alpha(9) . The companies will collaborate on preclinical R&D of the antibodies to treat autoimmune and bone diseases....